Published online before print May 25, 2006, doi: 10.1161/01.ATV.0000229218.97976.43
© 2006 American Heart Association, Inc.
Brief Reviews |
Scavenger Receptors in Atherosclerosis
Beyond Lipid Uptake
From the Lipid Metabolism Unit, Massachusetts General Hospital, Harvard Medical School, Boston.
Correspondence to Kathryn J. Moore, PhD, Lipid Metabolism Unit, GRJ1328, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114. E-mail kmoore{at}molbio.mgh.harvard.edu
 |
Abstract |
|---|
 Top Abstract IntroductionClass A SRsMacrophage Receptor With...Class B SRsCD36SR-BI and SR-BIIClass D SRs: CD68...Class E SRs: LOX-1Class F SRs: SREC-I...Class G SRs: SR-PSOXAlternative Pathways of Foam...References |
|---|
Atherosclerotic vascular disease arises as a consequence of the deposition and retention of serum lipoproteins in the artery wall. Macrophages in lesions have been shown to express
6 structurally different scavenger receptors for uptake of modified forms of low-density lipoproteins (LDLs) that promote the cellular accumulation of cholesterol. Because cholesterol-laden macrophage foam cells are the primary component of the fatty streak, the earliest atherosclerotic lesion, lipid uptake by these pathways has long been considered a requisite and initiating event in the pathogenesis of atherosclerosis. Although the removal of proinflammatory modified LDLs from the artery wall via scavenger receptors would seem beneficial, the pathways distal to scavenger receptor uptake that metabolize the modified lipoproteins appear to become overwhelmed, leading to the accumulation of cholesterol-laden macrophages and establishment of a chronic inflammatory setting. These observations have led to the current dogma concerning scavenger receptors, which is that they are proatherogenic molecules. However, recent studies suggest that the effects of scavenger receptors on atherogenesis may be more complex. In addition to modified lipoprotein uptake, these proteins are now known to regulate apoptotic cell clearance, initiate signal transduction, and serve as pattern recognition receptors for pathogens, activities that may contribute both to proinflammatory and anti-inflammatory forces regulating atherogenesis. In this review, we focus on recent advances in our knowledge of scavenger receptor regulation and signal transduction, their roles in sterile inflammation and infection, and the potential impact of these pathways in regulating the balance of lipid accumulation and inflammation in the artery wall. Atherosclerosis arises from the deposition and retention of serum lipoproteins in the artery wall. Macrophage scavenger receptors bind modified lipoproteins and promote cellular cholesterol accumulation in the artery wall. This review focuses on recent advances in scavenger receptor regulation and signal transduction, and highlights their roles in lipid accumulation and inflammation.
|
Introduction |
|---|
|
TopAbstractIntroductionClass A SRsMacrophage Receptor With...Class B SRsCD36SR-BI and SR-BIIClass D SRs: CD68...Class E SRs: LOX-1Class F SRs: SREC-I...Class G SRs: SR-PSOXAlternative Pathways of Foam...References |
|---|
The deposition and retention of serum lipoproteins in the artery wall, where they are susceptible to modification through oxidization and enzymatic action, is believed to activate an immune response that initiates the atherosclerotic lesion. The current paradigm suggests that accumulation of oxidized lipoproteins in the artery wall sets off a cascade of proinflammatory events leading to the recruitment of macrophages, lipid uptake into these cells, and the initiation of the chronic inflammatory cascade that characterizes atherosclerosis. Electron microscopy studies have established that the earliest atherosclerotic lesion, the fatty streak, consists almost entirely of lipid-laden macrophages, thus implicating lipoprotein uptake by these immune cells in the origination of atherosclerosis.1 These findings led to a search for lipoprotein receptors distinct from the low-density lipoprotein (LDL) receptor that could mediate cholesterol loading of macrophages. Macrophage scavenger receptors (SRs), first described by Brown and Goldstein, were found to bind and internalize modified forms of LDL through mechanisms not inhibited by cellular cholesterol content,2 identifying these receptors as likely culprits in macrophage cholesterol accumulation.
See cover
Since the cloning of the first macrophage SR (MSR) in 1990,3 the SR family has expanded to include 8 different subclasses of structurally unrelated receptors that share the defining feature of being able to bind modified forms of LDL. This family was aptly named because these receptors have subsequently been found to bind and "scavenge" a broad array of other modified self and nonself ligands, including apoptotic cells, anionic phospholipids, and amyloid and pathogen components.4 The SRs are thus believed to be members of the group of pattern recognition receptors that mediate the innate immune host response through recognition of highly conserved pathogen-associated molecular patterns. This evolutionarily ancient but highly effective system of host defense enables the immune system to discriminate between "noninfectious self" and "infectious nonself." However, there is a growing body of evidence to suggest that SRs may recognize endogenous neoantigens in oxidatively modified lipoproteins and apoptotic cells through molecular mimicry of microbial pathogen ligands. The EO6 monoclonal antibody that recognizes oxidized phosphorylcholine moieties present in oxidized LDL (oxLDL) that are known SR ligands has been shown to be identical to the T15 antibody identified independently in mice infected with Streptococcus pneumoniae.5 This suggests that the activation of innate immune pathways designed to protect us from pathogens may be responsible for initiating macrophage cholesterol loading and feeding the chronic inflammatory cascade that characterizes atherosclerosis.
Although the uptake of modified lipoproteins by SRs is thought to be central to foam cell formation, it is also widely believed to represent one of the major activation events stimulating the proinflammatory phenotype of lesional macrophages. In the last several years, it has come to be appreciated that SRs initiate signaling cascades that regulate macrophage activation, lipid metabolism, and inflammatory programs that may influence the development and stability of the atherosclerotic plaque. In addition, these receptors have roles in the induction of apoptosis, apoptotic cell clearance, and pathogen recognition that may differentially impact early and more complex lesions. These new insights suggest that the roles of SRs in atherosclerosis are more complex than originally envisioned, precipitating a renewed interest in understanding the contribution of these receptors to this multifactorial vascular disease.
Murphy et al recently published a comprehensive review of the biochemistry and cellular biology of SRs that details the genetics, protein expression, and membrane trafficking of SR family members.4 In this review, we focus on the SRs with established links to atherosclerosis (Figure 1) and the recent advances made in understanding the mechanisms by which these receptors may affect disease. The degree to which in vitro preparations of modified lipoproteins mimic in vivo lipoproteins is unknown, so particular emphasis is placed on receptors for which deletion has been shown to alter atherosclerosis in animal models. To date, there is genetic evidence that the A class SRs, SR-AI and SR-AII, and 2 members of the B class, CD36 and SR-BI, affect atherosclerotic lesion development. Roles have also been proposed for the class D, E, F, and G members, CD68, SR expressed by endothelial cells (SREC), SR-phosphatidylserine and oxidized lipoprotein (SR-PSOX),;AQ:5,6> and lectin-like oxidized LDL receptor (LOX-1), respectively, based on their ability to bind modified LDL and their expression in atherosclerotic lesions, but thus far, studies showing a direct impact of these receptors on atherogenesis in vivo are lacking. For the purposes of this review, we do not discuss the class C Drosophila dSR-C, which does not have a human homologue, class H FEEL1 and FEEL2, which have roles primarily in bacterial binding, nor the class I CD163, which has a proposed role in hemoglobin binding.
|
|
Class A SRs |
|---|
|
TopAbstractIntroductionClass A SRsMacrophage Receptor With...Class B SRsCD36SR-BI and SR-BIIClass D SRs: CD68...Class E SRs: LOX-1Class F SRs: SREC-I...Class G SRs: SR-PSOXAlternative Pathways of Foam...References |
|---|
The cloning of the defining member of the SR family, SR-A, was first reported in 1990 and was originally named MSR.3,6 This gene gives rise to 3 differentially spliced mRNAs that code for type I transmembrane receptors predominantly expressed in macrophages.6 When it became apparent that these receptors were part of a larger receptor family, they were designated as class A SRs and renamed SR-AI, SR-AII, and SR-AIII. The A class of SRs has grown to include 5 members that share common collagen-like domains and a homotrimeric structure: SR-AI, SR-AII, SR-AIII, macrophage receptor with collagenous structure (MARCO), and SR with C-type lectin.4
SR-AI and SR-AII have similar intracellular domains and collagen-domain containing stalks, but SR-AI has an additional cysteine-linked C-terminal extension of 110 amino acids.6 Despite this distinction, no major differences in ligand binding have been detected between these 2 splice products. The more recently described SR-AIII appears to be retained in the endoplasmic reticulum and is not accessible to extracellular ligands, thus its functional significance is uncertain.7 SR-AI and SR-AII are expressed on the cell surface of tissue macrophages, including macrophage foam cells, and have been detected on aortic endothelial cells and vascular smooth muscle cells within atherosclerotic plaque.8,9 Studies from our laboratory and others suggest that SR-AI and SR-AII account for the majority (
80%) of macrophage uptake of acetylated LDL but have a lower affinity for oxLDL.10,11 SR-AI and SR-AII preferentially bind more extensively oxLDL, recognizing the modified apolipoprotein B (apoB) protein component of this particle.12,13 In addition, SR-AI and SR-AII also bind apoptotic cells, ß-amyloid peptide, anionic phospholipids, and advanced glycation end-products.4 These receptors have also been implicated in both innate and adaptive immune responses through their recognition of pathogens and pathogen-associated molecules, including Gram-negative lipopolysaccharide and Neisseria meningitides and Gram-positive Staphylococcus aureus and Listeria monocytogenes.14
Initial studies of SR-AI and SR-AII null (Msr–/–) mice performed in atherosclerosis-susceptible apoE-deficient (Apoe–/–) mice on a hybrid background (ICR/129) fed a chow diet showed a 58% decrease in aortic sinus atherosclerosis lesion area compared with Apoe–/– littermates.10 However, subsequent evaluation in the LDL receptor null (Ldlr–/–) atherosclerosis model after 4 and 12 weeks on a high-fat diet showed more modest reductions in atherosclerotic lesion size (28% and 23%, respectively).15 Despite the difference in the magnitude of the effect of the Msr deletion in these 2 models, these early studies established the paradigm that lipid uptake via SR-A was proatherosclerotic. However, a third study of Msr deletion in the apoE3 Leiden hyperlipidemic mouse model showed 35% and 86% increases in lesion area in male and female mice, respectively; however, the SDs in lesion measurements were sufficiently large so that they failed to obtain statistical significance.16 The reason for these different findings is unknown; however, the Msr–/– mice used in all of these early studies were on a hybrid 129/ICR strain intercrossed into a genetically altered, hyperlipidemic mouse without extensive back-crossing into the atherosclerosis-susceptible C57BL/6 strain. It has since become appreciated that mouse strains differ in their atherosclerosis susceptibility, with 129 mice being more resistant than C57BL/6 mice, and that atherosclerotic lesion area can vary widely in same-generation mouse progeny of mixed backgrounds, with SDs of >70% being reported in F2 mice.17 Thus, these early investigations of SR-A function were likely confounded by variation at other genetic loci.
However, subsequent studies of SR-A deletion or overexpression in mice more fully back-crossed into the C57BL/6 background have led to equally confounding results, making the contribution of SR-A to atherogenesis controversial. Babaev et al reported 80% to 85% decline in lesion area in modestly hyperlipidemic Msr–/– mice back-bred 6 generations and fed a butterfat diet for 30 weeks.18 Similar findings were also seen in Ldlr–/– mice reconstituted with Msr–/– hematopoietic fetal liver cells, suggesting that macrophage expression of SR-A contributes significantly to the proatherosclerotic effect of SR-A.19 However, studies of overexpression of Msr in either the Ldlr–/– or Apoe–/– mouse model have both failed to show any evidence for exacerbation of atherosclerosis20,21 and resulted in a 74% reduction in atherosclerosis in the aortic arch.22 The most recent study of Msr deletion comes from work performed in our laboratory on mice back-bred 7 generations into C57BL/6 in the Apoe–/– background.23 After 8 weeks on a Western diet, Msr–/– male mice showed a 40% increase in aortic sinus lesion area; however, no difference in aortic sinus lesion area was noted in similarly treated female mice, nor was a difference detected in lesion area in the aortic tree in mice of either gender.23 A particularly intriguing finding was that the increase of atherosclerotic lesion area in male Msr–/– mice corresponded with a profound reduction in peritoneal macrophage foam cell formation in vivo, as measured by cellular cholesterol and cholesterol ester content. This reduction in in vivo foam cell formation was not apparent in female mice, and although the reason for this gender difference is unclear, the results suggest that lipid uptake by SRs, at least in male mice, may in fact protect against atherosclerosis lesion development.
The conflicting outcomes of these multiple studies on SR-A involvement in atherosclerosis are difficult to reconcile. The differences in genomic background, hypercholesterolemic mouse models, and diets used in the various studies are likely to have played a significant role in these divergent outcomes, and further studies will be needed to clarify this issue. Interestingly, comparisons of atherosclerosis-susceptible and -resistant mouse and rabbit models have shown that SR-A expression is increased in animals with low atherosclerotic responses, suggesting that this pathway is protective.24 Furthermore, overexpression of a secreted form of the human SR-A extracellular domain reduced monocyte/macrophage adherence to endothelial cells and atherosclerotic aortic lesion area in Ldlr–/– mice by 20%.25 Thus, the use of such decoy SRs may prove beneficial for retarding early atherosclerotic lesion development. However, because patients with overt coronary artery disease typically present at advanced stages of the disease when more complex plaques are present, this may not be an effective strategy for the treatment of human disease.
There is emerging evidence that SR-A plays different roles in early and advanced atherosclerotic lesions. In advanced atherosclerotic lesions, in which macrophage cell death leads to necrotic core formation and plaque destabilization, SR-A may have important roles in both the induction of apoptosis and the clearance of these dying cells. During hypercholesterolemia, macrophage pathways for metabolizing modified lipoproteins are believed to become overwhelmed, leading to a toxic accumulation of free cholesterol in the cell that results in endoplasmic reticular stress. In this setting, engagement of SR-A pathways by modified lipoproteins or fucoidan triggers apoptotic cell death, indicating that SR-A signaling contributes to macrophage death and necrotic core formation.26 However, this proatherosclerotic role is also balanced by the ability of SR-A to recognize and clear apoptotic cells in a nonphlogistic manner. These additional functions of SR-A must be considered when proposing therapies to block this pathway. Longer-term studies of SR-A manipulation (deletion or overexpression) will be required to determine the impact of this receptor at later stages of atherosclerosis.
|
Macrophage Receptor With Collagenous Structure |
|---|
|
TopAbstractIntroductionClass A SRsMacrophage Receptor With...Class B SRsCD36SR-BI and SR-BIIClass D SRs: CD68...Class E SRs: LOX-1Class F SRs: SREC-I...Class G SRs: SR-PSOXAlternative Pathways of Foam...References |
|---|
A novel member of the SR-A family was cloned in 1995 and named MARCO.4 This receptor is structurally similar to SR-AI in that it has an extracellular collagenous domain and a C-terminal cysteine-rich domain, but it lacks the
-helical coiled coil of the SR-As. In normal mice, MARCO expression is restricted to macrophages in the spleen marginal zone and lymph nodes, where it appears to play a role in cellular pathogen clearance. This receptor can bind both Gram-negative and -positive bacteria, and deletion of this gene in mice renders them more susceptible to infection with S pneumoniae.4 However, the roles of MARCO in binding modified LDL and in atherogenesis have been less well studied. |
Class B SRs |
|---|
|
TopAbstractIntroductionClass A SRsMacrophage Receptor With...Class B SRsCD36SR-BI and SR-BIIClass D SRs: CD68...Class E SRs: LOX-1Class F SRs: SREC-I...Class G SRs: SR-PSOXAlternative Pathways of Foam...References |
|---|
The B class of SRs was established with the identification of CD36 as a receptor for oxLDL.27 Unlike the SR-A family, CD36 is a type III (multiple transmembrane domains) receptor that traverses the membrane twice to form a heavily glycosylated extracellular loop with 2 short intracellular tails.4 This class contains 2 additional members with similar structure: SR-BI and lysosomal integral membrane protein–II. This gene family is believed to have evolved from a single ancestral gene that underwent duplication and dispersal in the genome. However, despite the high degree of homology of CD36 and SR-BI, these 2 receptors appear to play quite distinct roles in lipid metabolism and atherosclerosis.
|
CD36 |
|---|
|
TopAbstractIntroductionClass A SRsMacrophage Receptor With...Class B SRsCD36SR-BI and SR-BIIClass D SRs: CD68...Class E SRs: LOX-1Class F SRs: SREC-I...Class G SRs: SR-PSOXAlternative Pathways of Foam...References |
|---|
CD36 was originally identified in the late 1980s as glycoprotein IV, a platelet receptor that bound thrombospondin and Plasmodium falciparum parasitized erythrocytes.28,29 However, its role in lipid uptake was not recognized until 1993, when it was shown to be a macrophage receptor for moderately oxidized LDL.27 Unlike SR-AI and SR-AII, CD36 does not bind acetylated LDL or extensively oxidized LDL with high affinity and has a wider cellular distribution, including monocytes, macrophages, adipocytes, microvascular endothelium, platelets, and erythroid precursors.4 CD36 binds several ligands common to SR-A (ß-amyloid, anionic phospholipids, apoptotic cells, advanced glycation end-products);30–33 however, it is distinct from SR-A in its ability to bind native lipoproteins (LDL, high-density lipoprotein [HDL], and very low–density lipoprotein [VLDL]), as well as thrombospondin-1, collagen, fatty acids, and pathogen-derived ligands (P falciparum peptides, bacterial lipopeptides).28,34–36 As a result of its broad specificity, CD36 has been reported to contribute to a varied list of normal and pathologic processes such as apoptotic cell clearance, fatty acid transport, adhesion, angiogenesis, atherosclerosis, Alzheimer disease, and microbial defense.
Studies by our group and others indicate that CD36 plays a major role in the clearance of oxLDL, contributing 60% to 70% of cholesterol ester accumulation in macrophages exposed to LDL oxidized by Cu+2 and myeloperoxidase/peroxynitrite mechanism.11,37,38 A class of oxidized phosphatidylcholine molecules derived from oxidized PAPC (1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine) and PLPC (1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine) have been identified in oxidized lipoproteins as high-affinity CD36 ligands and shown to be enriched in atherosclerotic lesions.39–42 One of these ligands, POV-PC (1-palmytoyl-2-(5-oxovaleryl)-sn-glycero-3-phosphocholine), has been identified as the epitope recognized by the E06 anti-oxLDL antibody isolated from hyperlipidemic Apoe–/– mice.43 This oxidized phospholipid is also present on cells undergoing apoptosis, and EO6 can block the interaction of CD36 with oxLDL and apoptotic cells.40,44,45 Interestingly, this antibody was recently shown to be identical to the naturally occurring T15 antibody directed against S pneumoniae, suggesting that molecular mimicry of microbial ligands may play a role in the recognition of oxLDL by CD36.5 Immunization of animal models with S pneumoniae has been shown to partially suppress atherogenesis, indicating that these IgM responses may protect against atherosclerosis by inhibiting the interaction of CD36 with its ligands.46
Initial studies performed in Apoe–/– mice lacking CD36 reported marked reductions in atherosclerotic lesion area, supporting the paradigm that CD36-mediated oxLDL uptake is required for macrophage foam cell formation and atherosclerosis.38 After 12 weeks on a high-fat/high-cholesterol diet, mice lacking CD36 were found to have a 76% reduction in lesion area measured by en face analysis of lipid accumulation on the aortic surface. Measurement of atherosclerotic lesion area in cross-sections of the aortic sinus showed a 45% decrease in lesion area in male Apoe–/–Cd36–/– mice but no difference in female Apoe–/–Cd36–/– mice when compared with Apoe–/– control mice. In less hyperlipidemic mice fed a chow diet, a significant decrease in aortic sinus atherosclerosis was also noted in male Apoe–/–Cd36–/– mice, with a smaller, nonstatistically significant decrease in lesion area in female Apoe–/–Cd36–/– mice. Subsequent studies from our group and others have supported this proatherosclerotic role for CD36 in lesion formation in the descending aorta but not in the aortic sinus.23,47,48 Recently, we reported that despite reductions in peritoneal macrophage cholesterol ester accumulation in Cd36–/–Apoe–/– mice in vivo, lesion size in the aortic sinus was increased compared with Apoe–/– mice. After 8 weeks on a high-fat/high-cholesterol diet, cross-sectional analysis of the aortic sinus revealed 20% and 40% increases in lesion area in female and male Cd36–/–Apoe–/– mice, respectively.23 In contrast, en face analysis of lipid accumulation on the aortic surface showed a decrease in lesion area of 30% to 40% in the absence of CD36. Although this reduction was less dramatic than the previously reported 70% to 80% reduction in aortic lesion area,38 we attribute this disparity to the difference in the genetic background of the mice used (4 generations38 versus 7 generations back-crossed to C57BL623). Similar disparities have been noted in assessing the effect of Rag1 gene deletion: Ldlr–/–Rag1–/– mice were reported to have 65% to 70% reductions in aortic sinus atherosclerosis in mice that were genomically 93% C57BL/6, which, on further back-crossing, was reduced to 30% in mice that were 99% C57BL/6.49 This study emphasizes that atherosclerosis measurements in mice that are incompletely back-crossed can lead to confounding results. That being said, further studies continue to support a role for CD36 in atherosclerosis in the descending aorta. Transplantation of Cd36–/– bone marrow into Apoe–/– mice resulted in a large reduction in aortic en face lesion area in hypercholesterolemic mice, indicating that macrophage CD36 contributes to lesion progression in the aortic tree.47 Moreover, treatment of Apoe–/– mice with a CD36 ligand derived from growth hormone–releasing peptide EP80317 reduced aortic atherosclerotic lesion area by up to 50%.48 Together, these studies suggest that CD36 may differentially contribute to lesion development in the aortic sinus and the descending aorta. Whether this effect is attributable entirely to its lipid uptake function is not known.
It has become increasingly appreciated that in addition to mediating lipid uptake and apoptotic cell clearance, CD36 can promote proinflammatory signaling that may drive chronic inflammation in the artery wall. In the last several years, our group and others have described signaling pathways initiated by CD36 in response to thrombospondin, amyloid peptides (ß-amyloid, fibrillar apoC-II), and pathogen-derived ligands from P falciparum, Mycoplasma pneumoniae, and S aureus35,36,50–55; however, the signaling pathways triggered by CD36 engagement of oxLDL remain largely undefined.
The multiple signaling pathways induced via CD36 are illustrated in Figure 2, and several common observations with regard to these CD36 signaling pathways can be made: (1) CD36 can associate with Src kinases (Lyn, Fyn, Yes)51,54; (2) Src kinase activation leads to phosphorylation of mitogen-activated protein (MAP) kinase family members p38, p44/42, and c-Jun N-terminal kinase50,51,54,56; (3) CD36 interactions with Src and MAP kinases in different cell types can lead to diverse cellular and biologic consequences, including cell death,51 inflammatory gene expression,50,53,54,57 adhesion, and migration;56 and (4) CD36 may interact with different co- receptors to initiate different signaling responses.36,50,55 Although these findings have underscored the ability of CD36 to actively participate in signaling responses, many questions remain about the molecular mechanisms that regulate this process, particularly how CD36 signaling induces such divergent responses as noninflammatory clearance of apoptotic cells, proinflammatory cytokine responses to pathogens, and angiostatic cell death. One possibility is that CD36 cooperation with coreceptors regulates activation of these different signal transduction pathways. Two such interactions have been confirmed: cooperation of CD36 with members of the Toll-like receptor (TLR2 and TLR6) family, and members of the integrin (3ß1 and 6ß1) family.35,36,50,55,58,59 Recent reports from our group and others showed that CD36 activates signaling via TLR2 and TLR6 in response to the S aureus cell wall component lipoteichoic acid and the M pneumoniae diacylated lipopeptide macrophage-activity lipopeptide 2.35,36 The C-terminal cytoplasmic tail of CD36 was found to regulate both phagocytosis and activation of TLR2/6 signaling, and tyrosine 463 and cysteine 464 were identified as essential residues in this domain.36 Cysteine 464 was also identified as essential for CD36 association with ß1-integrin and the antiangiostatic effect of thrombospondin-1.55 However, whether these residues mediate interactions with TLRs or ß1-integrin or whether they promote kinase binding that regulates coreceptor activation is not known.
|
B (NF-In addition to atherosclerosis, CD36 has also been implicated in promoting chronic inflammation in Alzheimer disease.33,50,54,57 There has been considerable interest in a link between these 2 diseases because recent epidemiological studies have suggested a convergence of risk factors for Alzheimer disease and atherosclerosis, indicating that they may have overlapping mechanisms of pathogenesis. Work from our group and others has shown that CD36 binding of ß-amyloid fibrils that accumulate in Alzheimer disease initiates inflammatory signaling pathways leading to microglial activation, reactive oxygen production, and secretion of cytokines and chemokines.33,50,54,57 These responses contribute significantly to neuronal degeneration in the Alzheimer brain, and interruption of CD36 signaling pathways blocks the recruitment of microglia to amyloid deposits in the brain.54,57 Interestingly, amyloid ligands, including ß-amyloid and fibrillar apolipoproteins (C-II, A-I), have also been detected in human atheroma, and these ligands can initiate proinflammatory CD36 signaling that may drive inflammation in the artery wall.53,60
|
SR-BI and SR-BII |
|---|
|
TopAbstractIntroductionClass A SRsMacrophage Receptor With...Class B SRsCD36SR-BI and SR-BIIClass D SRs: CD68...Class E SRs: LOX-1Class F SRs: SREC-I...Class G SRs: SR-PSOXAlternative Pathways of Foam...References |
|---|
SR-BI was first discovered by its homology to CD36, and a differential splice variant differing in the C-terminal cytoplasmic domain was subsequently identified as SR-BII.61–63 SR-BI is more efficiently translated, representing 88% of immunodetectable SR-BI and SR-BII protein in mouse liver, and thus the majority of studies have focused on this isoform.63 SR-BI and SR-BII share
30% amino acid sequence homology with CD36 and, like this receptor, can bind both modified forms of LDL as well as native HDL, LDL, and VLDL.62,64 In addition, SR-BI recognizes typical SR ligands, including apoptotic cells, advanced glycation end-products, anionic phospholipids, serum amyloid A, and ß-amyloid.30,65–67 However, despite their high homology and similar ligand repertoire, CD36 and SR-BI have very distinct functions in lipoprotein metabolism. Although both bind HDL with high affinity, SR-BI facilitates selective cholesterol uptake from and transfer to HDL, marking it as an important player in reverse cholesterol transport.64 SR-BI is highly expressed in the liver and macrophages, as well as steroidogenic tissues such as the adrenal glands, ovaries, and testes that have a continuous demand for cholesterol.64 This receptor has a major impact on lipoprotein metabolism through 2 mechanisms: (1) SR-BI mediates cholesterol transfer from cells to HDL, and (2) SR-BI facilitates the selective delivery of this cholesterol from HDL to steroidogenic tissues and to the liver for excretion into bile and feces. Unlike the endocytic mechanism used by the LDL receptor, SR-BI uptake of HDL cholesterol occurs by selective transfer of HDL-derived lipids into cells without HDL particle degradation. Gene deletion and overexpression studies have illustrated the physiological importance of the dual roles of SR-BI in HDL metabolism. Targeted deletion of SR-BI in mice leads to hypercholesterolemia primarily because of increased HDL levels and reduced biliary cholesterol secretion, whereas overexpression of SR-BI by transgenesis or adenoviral-mediated gene transfer is associated with decreased levels of HDL.68–70 In rabbits, an animal model that expresses cholesterol ester transfer protein as in humans, SR-BI overexpression is also associated with increased levels of apoB-containing lipoproteins.71 The impact of SR-BI on atherosclerosis has been evaluated in several mouse models, and this gene is considered for the most part to play an antiatherosclerotic role. Although mice lacking SR-BI do not spontaneously develop atherosclerosis, when placed on a high-fat/high-cholesterol diet, they develop significantly greater atherosclerosis at the aortic sinus than their wild-type counterparts.68,72,73 Atherosclerosis is dramatically worsened in Srb1–/– mice also deficient in apoE. On a chow diet, Srb1–/–Apoe–/– mice exhibit many of the hallmarks of human coronary disease, including occlusive coronary atherosclerosis, spontaneous myocardial infarction, and cardiac hypertrophy and dysfunction.72 This severe phenotype results in their premature death at 6 weeks of age, limiting the usefulness of these mice as a model of human disease. However, this constraint was recently overcome by crossing the Srb1–/– mice onto a hypomorphic apoE (ApoeR61h/h) background to generate a diet-inducible model of occlusive coronary atherosclerosis that should facilitate studies of the role of SR-BI in the pathophysiology of atherosclerosis.74
The role of SR-BI in atherosclerosis has also been examined in the Ldlr–/– mouse model. Hepatic overexpression of SR-BI in these mice by either transgenesis or adenovirus-mediated gene transfer significantly protects against the development of atherosclerosis,75–77 whereas global deletion of SR-BI increases atherosclerotic lesion development.78 Although the antiatherogenic effects of SR-BI have been largely attributed to its ability to mediate cholesterol ester uptake from HDL to the liver, this receptor is highly expressed on macrophage foam cells in human and mouse atherosclerotic lesions, where it may influence lesion development through both the uptake of lipoproteins and the efflux of cholesterol to HDL. Two studies of Srb1–/– bone marrow transplantation into Ldlr–/– or Apoe–/– mice have suggested an atheroprotective role for macrophage SR-BI.78,79 However, a third transplantation study in Ldlr–/– mice that examined the effect of macrophage SR-BI on both early and advanced atherosclerosis suggests that its role may be more complex. Although SR-BI on macrophages was found to reduce the development of advanced atherosclerotic lesions (9 and 12 weeks of Western diet), in early lesions (4 weeks of Western diet), macrophage SR-BI appeared to promote fatty streak formation.80 Thus, depending on the context, macrophage SR-BI may be either proatherosclerotic or antiatherosclerotic, and this is likely a result of its multifunctional and multiligand qualities.
|
Class D SRs: CD68 and Macrosialin |
|---|
|
TopAbstractIntroductionClass A SRsMacrophage Receptor With...Class B SRsCD36SR-BI and SR-BIIClass D SRs: CD68...Class E SRs: LOX-1Class F SRs: SREC-I...Class G SRs: SR-PSOXAlternative Pathways of Foam...References |
|---|
CD68 and its murine homolog macrosialin are heavily glycosylated type I transmembrane proteins that are predominantly expressed in late endosomes and lysosomes of macrophages.81 These receptors were identified as oxLDL binding proteins through ligand blotting experiments; however, based on their expression pattern, they are unlikely to play a major role in oxLDL internalization.82 However, these proteins may contribute to oxLDL endolysosomal processing. Levels of macrosialin are upregulated by oxLDL, and this receptor is expressed in macrophage foam cells in atherosclerotic plaques of Apoe–/– mice,82 but further studies of its role in atherogenesis await the generation of a macrosialin knockout mouse.
|
Class E SRs: LOX-1 |
|---|
|
TopAbstractIntroductionClass A SRsMacrophage Receptor With...Class B SRsCD36SR-BI and SR-BIIClass D SRs: CD68...Class E SRs: LOX-1Class F SRs: SREC-I...Class G SRs: SR-PSOXAlternative Pathways of Foam...References |
|---|
LOX-1 is a lectin-like, type II transmembrane protein that was identified as a receptor for oxLDL in bovine aortic endothelial cells83 and subsequently shown to bind other SR ligands, including advanced glycation end-products, apoptotic cells, and bacteria.84 LOX-1 is also expressed on macrophages and vascular smooth muscle and is present in atherosclerotic lesions of humans and hyperlipidemic mice.85,86 Recently, endothelial overexpression of LOX-1 in Apoe–/– mice was shown to enhance oxLDL uptake and accelerate intramyocardial vasculopathology.87 Further clarification of the role of LOX-1 in atherosclerosis awaits studies of a Lox1–/– mouse.
|
Class F SRs: SREC-I and SREC-II |
|---|
|
TopAbstractIntroductionClass A SRsMacrophage Receptor With...Class B SRsCD36SR-BI and SR-BIIClass D SRs: CD68...Class E SRs: LOX-1Class F SRs: SREC-I...Class G SRs: SR-PSOXAlternative Pathways of Foam...References |
|---|
SRs expressed by endothelial cells, SREC-I, and SREC-II, are type I transmembrane receptors containing N-terminal epidermal growth factor–like domains, a transmembrane domain, and a long cytoplasmic tail postulated to induce signal transduction.4 These 2 receptors share 35% homology, and although both bind modified LDL, only SREC-1 internalizes these ligands for degradation. Studies in Srec1–/– macrophages demonstrated that this receptor accounts for only 6% of total acetylated LDL degradation, suggesting that it plays a minor role in foam cell formation; however, studies in mouse models of atherosclerosis are still pending.14
|
Class G SRs: SR-PSOX |
|---|
|
TopAbstractIntroductionClass A SRsMacrophage Receptor With...Class B SRsCD36SR-BI and SR-BIIClass D SRs: CD68...Class E SRs: LOX-1Class F SRs: SREC-I...Class G SRs: SR-PSOXAlternative Pathways of Foam...References |
|---|
SR-PSOX was identified by its ability to bind oxLDL and was subsequently shown to be identical to the membrane-bound CXC chemokine CXCL16.4 This receptor is expressed in human and mouse atherosclerotic lesions, where it is present on endothelium, smooth muscle, and macrophages. To date, the contribution of SR-PSOX to macrophage oxLDL uptake, foam cell formation, and atherosclerosis is unclear; however, one study suggests an association of a CXCL16 gene polymorphism with severity of coronary artery stenosis.88
|
Alternative Pathways of Foam Cell Formation |
|---|
|
TopAbstractIntroductionClass A SRsMacrophage Receptor With...Class B SRsCD36SR-BI and SR-BIIClass D SRs: CD68...Class E SRs: LOX-1Class F SRs: SREC-I...Class G SRs: SR-PSOXAlternative Pathways of Foam...References |
|---|
Despite the dominance of the SR paradigm, there is considerable evidence that LDL-derived lipids can enter macrophages via other pathways. Although monomeric LDL appears to require oxidation or acetylation to become a high-affinity ligand for the SRs, enzymatic modifications (eg, sphingomyelinase, phospholipase C, or secretory phospholipase A2) can lead to increased retention of lipoproteins by matrix proteoglycans and internalization by non–SR-mediated pathways.89 Furthermore, native LDL has been reported to be internalized via macropinocytosis of extracellular fluid.90 Because the concentrations of native LDL in human intimal samples typically exceed 100 mg/dL, these forms of LDL could provide substantially greater amounts of lipid than can be taken up by the SR pathways, which saturate at lipoprotein concentrations of 25 to 50 µg/mL.6 Thus, although there is substantial evidence that oxidized forms of LDL are produced in the arteries of both mice and men, definitive data to establish that the lipid that generates foam cells derives from these oxidized lipoproteins, as opposed to native, aggregated, or nonoxidatively modified forms of LDL, have not yet been obtained.
Summary
Our knowledge of SR biology and the role of these receptors in modified LDL clearance have increased greatly in the last 20 years. However, many questions remain regarding their roles in atherogenesis. Our current understanding suggests that SRs may be beneficial during the initial stages of atherogenesis through their ability to clear potentially deleterious modified lipoproteins that accumulate in the artery wall. As macrophage pathways for metabolizing lipoprotein-derived cholesterol become overwhelmed, the unregulated nature of these receptors results in their promotion of disease-causing foam cells and chronic inflammation. However, the effectiveness of therapies targeted at inhibiting SR pathways and decreasing modified lipoprotein clearance from the intima remain in question because the fate of these proinflammatory lipoproteins in the artery wall is unknown. Given the multiple cellular toxicities associated with exposure to oxidized lipoproteins, it is not clear why abrogating these uptake pathways should reduce damage to the artery wall. The emergence of conflicting results on the impact of these receptors in mouse models of atherosclerosis, combined with recent advances in our understanding of other functions of these SRs that may also affect lesion development, argue that additional work clarifying the role of these receptors in atherogenesis is still needed.
The recent discovery that CD36 cooperates with coreceptors, including the TLRs, to elicit signaling responses suggests a more complex model for SR function than previously presumed. SR responses may be influenced by the availability of these coreceptors, which could confer both tissue- and cell-specific regulation. The involvement of TLRs in mediating the SR response to modified-self ligands, such as oxLDL and ß-amyloid, is currently unknown. However, recent studies in mice lacking TLR4 or the TLR adaptor MyD88 suggest that TLR pathways play a role in atherogenesis in the absence of infection.91,92 The ligands activating these pathways and the involvement of SRs in mediating these responses are areas of intense investigation. Unraveling these additional pathways and their contributions to lipid metabolism and inflammation will likely be a central focus of SR research for several years to come.
|
Acknowledgments |
|---|
Disclosures
None.
|
Footnotes |
|---|
Original received March 29, 2006; final version accepted May 15, 2006.
|
References |
|---|
|
TopAbstractIntroductionClass A SRsMacrophage Receptor With...Class B SRsCD36SR-BI and SR-BIIClass D SRs: CD68...Class E SRs: LOX-1Class F SRs: SREC-I...Class G SRs: SR-PSOXAlternative Pathways of Foam...References |
|---|
1. Gerrity RG, Naito HK. Ultrastructural identification of monocyte-derived foam cells in fatty streak lesions. Artery. 1980; 8: 208–214.[Medline] [Order article via Infotrieve]
2. Brown MS, Goldstein JL, Krieger M, Ho YK, Anderson RG. Reversible accumulation of cholesteryl esters in macrophages incubated with acetylated lipoproteins. J Cell Biol. 1979; 82: 597–613.
3. Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature. 1990; 343: 531–535.[CrossRef][Medline] [Order article via Infotrieve]
4. Murphy JE, Tedbury PR, Homer-Vanniasinkam S, Walker JH, Ponnambalam S. Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis. 2005; 182: 1–15.[CrossRef][Medline] [Order article via Infotrieve]
5. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, Witztum JL. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest. 2000; 105: 1731–1740.[Medline] [Order article via Infotrieve]
6. Rohrer L, Freeman M, Kodama T, Penman M, Krieger M. Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II. Nature. 1990; 343: 570–572.[CrossRef][Medline] [Order article via Infotrieve]
7. Gough PJ, Greaves DR, Gordon S. A naturally occurring isoform of the human macrophage scavenger receptor (SR-A) gene generated by alternative splicing blocks modified LDL uptake. J Lipid Res. 1998; 39: 531–543.
8. Naito M, Suzuki H, Mori T, Matsumoto A, Kodama T, Takahashi K. Coexpression of type I and type II human macrophage scavenger receptors in macrophages of various organs and foam cells in atherosclerotic lesions. Am J Pathol. 1992; 141: 591–599.[Abstract]
9. Daugherty A, Cornicelli JA, Welch K, Sendobry SM, Rateri DL. Scavenger receptors are present on rabbit aortic endothelial cells in vivo. Arterioscler Thromb Vasc Biol. 1997; 17: 2369–2375.
10. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Kodama T, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 1997; 386: 292–296.[CrossRef][Medline] [Order article via Infotrieve]
11. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002; 277: 49982–49988.
12. Lougheed M, Steinbrecher UP. Mechanism of uptake of copper-oxidized low density lipoprotein in macrophages is dependent on its extent of oxidation. J Biol Chem. 1996; 271: 11798–11805.
13. Zhang H, Yang Y, Steinbrecher UP. Structural requirements for the binding of modified proteins to the scavenger receptor of macrophages. J Biol Chem. 1993; 268: 5535–5542.
14. Greaves DR, Gordon S. Thematic review series: the immune system and atherogenesis. Recent insights into the biology of macrophage scavenger receptors. J Lipid Res. 2005; 46: 11–20.
15. Sakaguchi H, Takeya M, Suzuki H, Hakamata H, Kodama T, Horiuchi S, Gordon S, van der Laan LJ, Kraal G, Ishibashi S, Kitamura N, Takahashi K. Role of macrophage scavenger receptors in diet-induced atherosclerosis in mice. Lab Invest. 1998; 78: 423–434.[Medline] [Order article via Infotrieve]
16. de Winther MP, Gijbels MJ, van Dijk KW, van Gorp PJ, suzuki H, Kodama T, Frants RR, Havekes LM, Hofker MH. Scavenger receptor deficiency leads to more complex atherosclerotic lesions in APOE3Leiden transgenic mice. Atherosclerosis. 1999; 144: 315–321.[CrossRef][Medline] [Order article via Infotrieve]
17. Dansky HM, Charlton SA, Sikes JL, Heath SC, Simantov R, Levin LF, Shu P, Moore KJ, Breslow JL, Smith JD. Genetic background determines the extent of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 1999; 19: 1960–1968.
18. Babaev VR, Gleaves LA, Carter KJ, Suzuki H, Kodama T, Fazio S, Linton MF. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Arterioscler Thromb Vasc Biol. 2000; 20: 2593–2599.
19. Linton MF, Fazio S. Class A scavenger receptors, macrophages, and atherosclerosis. Curr Opin Lipidol. 2001; 12: 489–495.[CrossRef][Medline] [Order article via Infotrieve]
20. Van Eck M, De Winther MP, Herijgers N, Havekes LM, Hofker MH, Groot PH, Van Berkel TJ. Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on cholesterol levels and atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2000; 20: 2600–2606.
21. Herijgers N, de Winther MP, Van Eck M, Havekes LM, Hofker MH, Hoogerbrugge PM, Van Berkel TJ. Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knockout mice. J Lipid Res. 2000; 41: 1402–1409.
22. Whitman SC, Rateri DL, Szilvassy SJ, Cornicelli JA, Daugherty A. Macrophage-specific expression of class A scavenger receptors in LDL receptor(–/–) mice decreases atherosclerosis and changes spleen morphology. J Lipid Res. 2002; 43: 1201–1208.
23. Moore KJ, Kunjathoor VV, Koehn SL, Manning JJ, Tseng AA, Silver JM, McKee M, Freeman MW. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest. 2005; 115: 2192–2201.[CrossRef][Medline] [Order article via Infotrieve]
24. Teupser D, Stein O, Burkhardt R, Nebendahl K, Stein Y, Thiery J. Scavenger receptor activity is increased in macrophages from rabbits with low atherosclerotic response: studies in normocholesterolemic high and low atherosclerotic response rabbits. Arterioscler Thromb Vasc Biol. 1999; 19: 1299–1305.
25. Jalkanen J, Leppanen P, Narvanen O, Greaves DR, Yla-Herttuala S. Adenovirus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor (SR-AI) in LDL receptor knock-out mice. Atherosclerosis. 2003; 169: 95–103.[CrossRef][Medline] [Order article via Infotrieve]
26. Devries-Seimon T, Li Y, Yao PM, Stone E, Wang Y, Davis RJ, Flavell R, Tabas I. Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. J Cell Biol. 2005; 171: 61–73.
27. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993; 268: 11811–11816.
28. Silverstein RL, Asch AS, Nachman RL. Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion. J Clin Invest. 1989; 84: 546–552.[Medline] [Order article via Infotrieve]
29. Oquendo P, Hundt E, Lawler J, Seed B. CD36 directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes. Cell. 1989; 58: 95–101.[CrossRef][Medline] [Order article via Infotrieve]
30. Rigotti A, Acton SL, Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem. 1995; 270: 16221–16224.
31. Ren Y, Silverstein RL, Allen J, Savill J. CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis. J Exp Med. 1995; 181: 1857–1862.
32. Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S, Nakayama H. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem. 2001; 276: 3195–3202.
33. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, Luster AD, Silverstein SC, El Khoury J. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer’s disease brains and can mediate production of reactive oxygen species in response to ß-amyloid fibrils. Am J Pathol. 2002; 160: 101–112.
34. Calvo D, Gomez-Coronado D, Suarez Y, Lasuncion MA, Vega MA. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J Lipid Res. 1998; 39: 777–788.
35. Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K, Sovath S, Shamel L, Hartung T, Zahringer U, Beutler B. CD36 is a sensor of diacylglycerides. Nature. 2005; 433: 523–527.[CrossRef][Medline] [Order article via Infotrieve]
36. Stuart LM, Deng J, Silver JM, Takahashi K, Tseng AA, Hennessy EJ, Ezekowitz RA, Moore KJ. Response to Staphylococcus aureus requires CD36-mediated phagocytosis triggered by the COOH-terminal cytoplasmic domain. J Cell Biol. 2005; 170: 477–485.
37. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP, Cohen PA, Frazier WA, Hoff HF, Hazen SL. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000; 105: 1095–1108.[Medline] [Order article via Infotrieve]
38. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000; 105: 1049–1056.[Medline] [Order article via Infotrieve]
39. Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, Palinski W, Schwenke D, Salomon RG, Sha W, Subbanagounder G, Fogelman AM, Berliner JA. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem. 1997; 272: 13597–13607.
40. Boullier A, Gillotte KL, Horkko S, Green SR, Friedman P, Dennis EA, Witztum JL, Steinberg D, Quehenberger O. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem. 2000; 275: 9163–9169.
41. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Febbraio M, Hajjar DP, Silverstein RL, Hoff HF, Salomon RG, Hazen SL. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem. 2002; 277: 38517–38523.
42. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Gugiu B, Fox PL, Hoff HF, Salomon RG, Hazen SL. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem. 2002; 277: 38503–38516.
43. Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 1996; 98: 800–814.[Medline] [Order article via Infotrieve]
44. Horkko S, Bird DA, Miller E, Itabe H, Leitinger N, Subbanagounder G, Berliner JA, Friedman P, Dennis EA, Curtiss LK, Palinski W, Witztum JL. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999; 103: 117–128.[Medline] [Order article via Infotrieve]
45. Chang MK, Bergmark C, Laurila A, Horkko S, Han KH, Friedman P, Dennis EA, Witztum JL. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci U S A. 1999; 96: 6353–6358.
46. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, Silverman GJ. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med. 2003; 9: 736–743.[CrossRef][Medline] [Order article via Infotrieve]
47. Febbraio M, Guy E, Silverstein RL. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24: 2333–2338.
48. Marleau S, Harb D, Bujold K, Avallone R, Iken K, Wang Y, Demers A, Sirois MG, Febbraio M, Silverstein RL, Tremblay A, Ong H. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J. 2005; 19: 1869–1871.
49. Reardon CA, Blachowicz L, Lukens J, Nissenbaum M, Getz GS. Genetic background selectively influences innominate artery atherosclerosis: immune system deficiency as a probe. Arterioscler Thromb Vasc Biol. 2003; 23: 1449–1454.
50. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci. 2003; 23: 2665–2674.
51. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000; 6: 41–48.[CrossRef][Medline] [Order article via Infotrieve]
52. McGilvray ID, Serghides L, Kapus A, Rotstein OD, Kain KC. Nonopsonic monocyte/macrophage phagocytosis of Plasmodium falciparum-parasitized erythrocytes: a role for CD36 in malarial clearance. Blood. 2000; 96: 3231–3240.
53. Medeiros LA, Khan T, El Khoury JB, Pham CL, Hatters DM, Howlett GJ, Lopez R, O’Brien KD, Moore KJ. Fibrillar amyloid protein present in atheroma activates CD36 signal transduction. J Biol Chem. 2004; 279: 10643–10648.
54. Moore KJ, El Khoury J, Medeiros LA, Terada K, Geula C, Luster AD, Freeman MW. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem. 2002; 277: 47373–47379.
55. Primo L, Ferrandi C, Roca C, Marchio S, di Blasio L, Alessio M, Bussolino F. Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB J. 2005; 19: 1713–1715.
56. Yipp BG, Robbins SM, Resek ME, Baruch DI, Looareesuwan S, Ho M. Src-family kinase signaling modulates the adhesion of Plasmodium falciparum on human microvascular endothelium under flow. Blood. 2003; 101: 2850–2857.
57. El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, Freeman MW, Luster AD. CD36 mediates the innate host response to beta-amyloid. J Exp Med. 2003; 197: 1657–1666.
58. Koenigsknecht J, Landreth G. Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J Neurosci. 2004; 24: 9838–9846.
59. Thorne RF, Marshall JF, Shafren DR, Gibson PG, Hart IR, Burns GF. The integrins alpha3beta1 and alpha6beta1 physically and functionally associate with CD36 in human melanoma cells. Requirement for the extracellular domain OF CD36. J Biol Chem. 2000; 275: 35264–35275.
60. De Meyer GR, De Cleen DM, Cooper S, Knaapen MW, Jans DM, Martinet W, Herman AG, Bult H, Kockx MM. Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ Res. 2002; 90: 1197–1204.
61. Calvo D, Vega MA. Identification, primary structure, and distribution of CLA-1, a novel member of the CD36/LIMPII gene family. J Biol Chem. 1993; 268: 18929–18935.
62. Acton SL, Scherer PE, Lodish HF, Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem. 1994; 269: 21003–21009.
63. Webb NR, de Villiers WJ, Connell PM, de Beer FC, van der Westhuyzen DR. Alternative forms of the scavenger receptor BI (SR-BI). J Lipid Res. 1997; 38: 1490–1495.[Abstract]
64. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996; 271: 518–520.[Abstract]
65. Cai L, de Beer MC, de Beer FC, van der Westhuyzen DR. Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem. 2005; 280: 2954–2961.
66. Murao K, Terpstra V, Green SR, Kondratenko N, Steinberg D, Quehenberger O. Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. J Biol Chem. 1997; 272: 17551–17557.
67. Husemann J, Loike JD, Kodama T, Silverstein SC. Scavenger receptor class B type I (SR-BI) mediates adhesion of neonatal murine microglia to fibrillar beta-amyloid. J Neuroimmunol. 2001; 114: 142–150.[CrossRef][Medline] [Order article via Infotrieve]
68. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A. 1997; 94: 12610–12615.
69. Mardones P, Quinones V, Amigo L, Moreno M, Miquel JF, Schwarz M, Miettinen HE, Trigatti B, Krieger M, VanPatten S, Cohen DE, Rigotti A. Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice. J Lipid Res. 2001; 42: 170–180.
70. Ueda Y, Royer L, Gong E, Zhang J, Cooper PN, Francone O, Rubin EM. Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol Chem. 1999; 274: 7165–7171.
71. Tancevski I, Frank S, Massoner P, Stanzl U, Schgoer W, Wehinger A, Fievet C, Eller P, Patsch JR, Ritsch A. Increased plasma levels of LDL cholesterol in rabbits after adenoviral overexpression of human scavenger receptor class B type I. J Mol Med. 2005; 83: 927–932.[CrossRef][Medline] [Order article via Infotrieve]
72. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM, Rosenberg RD, Schrenzel M, Krieger M. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res. 2002; 90: 270–276.
73. Van Eck M, Twisk J, Hoekstra M, Van Rij BT, Van der Lans CA, Bos IS, Kruijt JK, Kuipers F, Van Berkel TJ. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem. 2003; 278: 23699–23705.
74. Zhang S, Picard MH, Vasile E, Zhu Y, Raffai RL, Weisgraber KH, Krieger M. Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice. Circulation. 2005; 111: 3457–3464.
75. Wang N, Arai T, Ji Y, Rinninger F, Tall AR. Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice. J Biol Chem. 1998; 273: 32920–32926.
76. Kozarsky KF, Donahee MH, Glick JM, Krieger M, Rader DJ. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol. 2000; 20: 721–727.
77. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 1997; 387: 414–417.[CrossRef][Medline] [Order article via Infotrieve]
78. Covey SD, Krieger M, Wang W, Penman M, Trigatti BL. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler Thromb Vasc Biol. 2003; 23: 1589–1594.
79. Zhang W, Yancey PG, Su YR, Babaev VR, Zhang Y, Fazio S, Linton MF. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation. 2003; 108: 2258–2263.
80. Van Eck M, Bos IS, Hildebrand RB, Van Rij BT, Van Berkel TJ. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Am J Pathol. 2004; 165: 785–794.
81. Ramprasad MP, Fischer W, Witztum JL, Sambrano GR, Quehenberger O, Steinberg D. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc Natl Acad Sci U S A. 1995; 92: 9580–9584.
82. de Beer MC, Zhao Z, Webb NR, van der Westhuyzen DR, de Villiers WJ. Lack of a direct role for macrosialin in oxidized LDL metabolism. J Lipid Res. 2003; 44: 674–685.
83. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997; 386: 73–77.[CrossRef][Medline] [Order article via Infotrieve]
84. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res. 2006; 69: 36–45.
85. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T, Sawamura T, Masaki T, Hashimoto N, Kita T. Expression of lectin-like oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation. 1999; 99: 3110–3117.
86. Chen M, Kakutani M, Minami M, Kataoka H, Kume N, Narumiya S, Kita T, Masaki T, Sawamura T. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol. 2000; 20: 1107–1115.
87. Inoue K, Arai Y, Kurihara H, Kita T, Sawamura T. Overexpression of lectin-like oxidized low-density lipoprotein receptor-1 induces intramyocardial vasculopathy in apolipoprotein E-null mice. Circ Res. 2005; 97: 176–184.
88. Lundberg GA, Kellin A, Samnegard A, Lundman P, Tornvall P, Dimmeler S, Zeiher AM, Hamsten A, Hansson GK, Eriksson P. Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR-PSOX gene. J Intern Med. 2005; 257: 415–422.[CrossRef][Medline] [Order article via Infotrieve]
89. Kruth HS, Huang W, Ishii I, Zhang WY. Macrophage foam cell formation with native low density lipoprotein. J Biol Chem. 2002; 277: 34573–34580.
90. Kruth HS, Jones NL, Huang W, Zhao B, Ishii I, Chang J, Combs CA, Malide D, Zhang WY. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native LDL. J Biol Chem. 2005; 280: 2352–2360.
91. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004; 10: 416–421.[CrossRef][Medline] [Order article via Infotrieve]
92. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A. 2004; 101: 10679–10684.
This article has been cited by other articles:
 |
|
 |
|
  C. Iacobini, S. Menini, C. Ricci, A. Scipioni, V. Sansoni, S. Cordone, M. Taurino, M. Serino, G. Marano, M. Federici, et al. Accelerated Lipid-Induced Atherogenesis in Galectin-3-Deficient Mice: Role of Lipoxidation via Receptor-Mediated Mechanisms Arterioscler. Thromb. Vasc. Biol., June 1, 2009; 29(6): 831 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Kim, H. Moradi, J. Yuan, K. Norris, and N. D. Vaziri Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1297 - F1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Silverstein and M. Febbraio CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior Sci. Signal., May 26, 2009; 2(72): re3 - re3. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Boyanovsky, M. Zack, K. Forrest, and N. R. Webb The Capacity of Group V sPLA2 to Increase Atherogenicity of ApoE-/- and LDLR-/- Mouse LDL In Vitro Predicts its Atherogenic Role In Vivo Arterioscler. Thromb. Vasc. Biol., April 1, 2009; 29(4): 532 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shrestha, S. J. Ehlers, J.-Y. Lee, M.-L. Fernandez, and S. I. Koo Dietary Green Tea Extract Lowers Plasma and Hepatic Triglycerides and Decreases the Expression of Sterol Regulatory Element-Binding Protein-1c mRNA and Its Responsive Genes in Fructose-Fed, Ovariectomized Rats J. Nutr., April 1, 2009; 139(4): 640 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Okamura, S. Pennathur, K. Pasichnyk, J. M. Lopez-Guisa, S. Collins, M. Febbraio, J. Heinecke, and A. A. Eddy CD36 Regulates Oxidative Stress and Inflammation in Hypercholesterolemic CKD J. Am. Soc. Nephrol., March 1, 2009; 20(3): 495 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Helming, J. Winter, and S. Gordon The scavenger receptor CD36 plays a role in cytokine-induced macrophage fusion J. Cell Sci., February 15, 2009; 122(4): 453 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Manning-Tobin, K. J. Moore, T. A. Seimon, S. A. Bell, M. Sharuk, J. I. Alvarez-Leite, M. P.J. de Winther, I. Tabas, and M. W. Freeman Loss of SR-A and CD36 Activity Reduces Atherosclerotic Lesion Complexity Without Abrogating Foam Cell Formation in Hyperlipidemic Mice Arterioscler. Thromb. Vasc. Biol., January 1, 2009; 29(1): 19 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Liao, X. Wang, M. Li, P. H. Lin, Q. Yao, and C. Chen Human protein S inhibits the uptake of AcLDL and expression of SR-A through Mer receptor tyrosine kinase in human macrophages Blood, January 1, 2009; 113(1): 165 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Lamon and D. P. Hajjar Inflammation at the Molecular Interface of Atherogenesis: An Anthropological Journey Am. J. Pathol., November 1, 2008; 173(5): 1253 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rayner, Y.-X. Chen, M. McNulty, T. Simard, X. Zhao, D. J. Wells, J. de Belleroche, and E. R. O'Brien Extracellular Release of the Atheroprotective Heat Shock Protein 27 Is Mediated by Estrogen and Competitively Inhibits acLDL Binding to Scavenger Receptor-A Circ. Res., July 18, 2008; 103(2): 133 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Gleissner, J. M. Sanders, J. Nadler, and K. Ley Upregulation of Aldose Reductase During Foam Cell Formation as Possible Link Among Diabetes, Hyperlipidemia, and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1137 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Malarstig, S. Sigurdsson, P. Eriksson, G. Paulsson-Berne, U. Hedin, L. Wallentin, A. Siegbahn, A. Hamsten, and A.-C. Syvanen Variants of the Interferon Regulatory Factor 5 Gene Regulate Expression of IRF5 mRNA in Atherosclerotic Tissue But Are Not Associated With Myocardial Infarction Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 975 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kim, A. T. Tolhurst, L. Y. Qin, X.-Y. Chen, M. Febbraio, and S. Cho CD36/Fatty Acid Translocase, An Inflammatory Mediator, Is Involved in Hyperlipidemia-Induced Exacerbation in Ischemic Brain Injury J. Neurosci., April 30, 2008; 28(18): 4661 - 4670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Siegel-Axel, K. Daub, P. Seizer, S. Lindemann, and M. Gawaz Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis Cardiovasc Res, April 1, 2008; 78(1): 8 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Greenberg, X.-M. Li, B. G. Gugiu, X. Gu, J. Qin, R. G. Salomon, and S. L. Hazen The Lipid Whisker Model of the Structure of Oxidized Cell Membranes J. Biol. Chem., January 25, 2008; 283(4): 2385 - 2396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. V. Limmon, M. Arredouani, K. L. McCann, R. A. C. Minor, L. Kobzik, and F. Imani Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA FASEB J, January 1, 2008; 22(1): 159 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sun, B. B. Boyanovsky, M. A. Connelly, P. Shridas, D. R. van der Westhuyzen, and N. R. Webb Distinct mechanisms for OxLDL uptake and cellular trafficking by class B scavenger receptors CD36 and SR-BI J. Lipid Res., December 1, 2007; 48(12): 2560 - 2570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Jagavelu, U. J.F. Tietge, M. Gaestel, H. Drexler, B. Schieffer, and U. Bavendiek Systemic Deficiency of the MAP Kinase Activated Protein Kinase 2 Reduces Atherosclerosis in Hypercholesterolemic Mice Circ. Res., November 26, 2007; 101(11): 1104 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Collot-Teixeira, J. Martin, C. McDermott-Roe, R. Poston, and J. L. McGregor CD36 and macrophages in atherosclerosis Cardiovasc Res, August 1, 2007; 75(3): 468 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Gleissner, N. Leitinger, and K. Ley Effects of Native and Modified Low-Density Lipoproteins on Monocyte Recruitment in Atherosclerosis Hypertension, August 1, 2007; 50(2): 276 - 283. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Maleszewski, J. Lu, K. Fox-Talbot, and M. K. Halushka Robust Immunohistochemical Staining of Several Classes of Proteins in Tissues Subjected to Autolysis J. Histochem. Cytochem., June 1, 2007; 55(6): 597 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ohwaki, H. Bujo, M. Jiang, H. Yamazaki, W. J. Schneider, and Y. Saito A Secreted Soluble Form of LR11, Specifically Expressed in Intimal Smooth Muscle Cells, Accelerates Formation of Lipid-Laden Macrophages Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1050 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C.H. Kwan, F. Kronenberg, S. Beddhu, and A. K. Cheung Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1246 - 1261. [Full Text] [PDF]
|
|
|
|
|
|
M.-D. Wang, R. S. Kiss, V. Franklin, H. M. McBride, S. C. Whitman, and Y. L. Marcel Different cellular traffic of LDL-cholesterol and acetylated LDL-cholesterol leads to distinct reverse cholesterol transport pathways J. Lipid Res., March 1, 2007; 48(3): 633 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. Parks, A. J. Lusis, and J. H.S. Kabarowski Loss of the Lysophosphatidylcholine Effector, G2A, Ameliorates Aortic Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2703 - 2709. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||